In the labyrinths of pathogenesis: the environment and metamorphosis of IBD
https://doi.org/10.21886/2712-8156-2021-2-3-30-39
Abstract
The purpose of this review is to combine evidence from studies based on environmental impacts on inflammatory bowel disease. The review reflects the environmental factors influencing the incidence of IBD, and also considers the predictors that modify the course of the diseases.
About the Authors
A. V. Tkachev
Rostov State Medical University
Russian Federation
Russian Federation
Alexander V. Tkachev, Dr. Sci. (Med.), professor, head of propaedeutics of internal disease
Rostov-on-Don
L. S. Mkrtchyan
Rostov State Medical University
Russian Federation
Russian Federation
Lilit S. Mkrtchyan, Assistant Professor of department of propaedeutics of internal disease
Rostov-on-Don
K. E. Mazovka
Rostov State Medical University
Russian Federation
Russian Federation
Karina E. Mazovka, Cand. Sci. (Med.), Assistant Professor of department of propaedeutics of internal disease
Rostov-on-Don
E. G. Bohanova
Rostov State Medical University
Russian Federation
Russian Federation
Elena G. Bohanova, Cand. Sci. (Med.), Assistant Professor of department of propaedeutics of internal disease
Rostov-on-Don
References
1. Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21(4):408-13. PMID: 15930979.
2. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103(12):3167-82. doi: 10.1111/j.1572-0241.2008.02158.x
3. Румянцев В.Г. Язвенный колит: руководство для врачей. М.: ООО «Медицинское информационное агентство»; 2009. ISBN: 978-5-8948-1777-4
4. Белоусова Е.А. Язвенный колит и болезнь Крона. Тверь: ООО «Издательство «Триада», 2002. ISBN: 5-94789-015-1
5. Дорофеев А.Э., Звягинцева Т.Д., Харченко Н.В. Заболевания кишечника. Горловка: Ліхтар; 2010.
6. Goh K, Xiao SD. Inflammatory bowel disease: a survey of the epidemiology in Asia. J Dig Dis. 2009;10(1):1-6. doi: 10.1111/j.1751-2980.2008.00355.x
7. Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China. J Dig Dis. 2010;11(2):76-82. doi: 10.1111/j.1751-2980.2010.00421.x
8. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis. 2010;11(3):134-47. doi: 10.1111/j.1751-2980.2010.00429.x
9. Shanahan F. The gut microbiota-a clinical perspective on lessons learned. Nat Rev Gastroenterol Hepatol. 2012;9(10):609-14. doi: 10.1038/nrgastro.2012.145
10. Mayberry J, Mann R. Inflammatory bowel disease in rural sub-Saharan Africa: rarity of diagnosis in patients attending mission hospitals. Digestion. 1989;44(3):172-6. doi: 10.1159/000199907
11. Soon IS, Molodecky NA, Rabi DM, Ghali WA, Barkema HW, Kaplan GG. The relationship between urban environment and the inflammatory bowel diseases: a systematic review and meta-analysis. BMC Gastroenterol. 2012;12:51. doi: 10.1186/1471-230X-12-51
12. Noverr MC, Huffnagle GB. The ‘microflora hypothesis’ of allergic diseases. Clin Exp Allergy. 2005;35(12):1511-20. doi: 10.1111/j.1365-2222.2005.02379.x
13. Leong RW, Mitrev N, Ko Y. Hygiene Hypothesis: Is the Evidence the Same All Over the World? Dig Dis. 2016;34(1-2):35-42. doi: 10.1159/000442922
14. Muegge BD, Kuczynski J, Knights D, Clemente JC, González A, Fontana L, et al. Diet drives convergence in gut microлитеРатУРа / rEFErEnCES biome functions across mammalian phylogeny and within humans. Science. 2011;332(6032):970-4. doi: 10.1126/science.1198719
15. Dominguez-Bello MG, Blaser MJ, Ley RE, Knight R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology. 2011;140(6):1713-9. doi: 10.1053/j.gastro.2011.02.011
16. Chapman-Kiddell CA, Davies PS, Gillen L, Radford-Smith GL. Role of diet in the development of inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(1):137-51. doi: 10.1002/ibd.20968
17. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106(4):563-73. doi: 10.1038/ajg.2011.44
18. Ma X, Torbenson M, Hamad AR, Soloski MJ, Li Z. High-fat diet modulates non-CD1d-restricted natural killer T cells and regulatory T cells in mouse colon and exacerbates experimental colitis. Clin Exp Immunol. 2008;151(1):130-8. doi: 10.1111/j.1365-2249.2007.03530.x
19. Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology. 2013;145(5):970-7. doi: 10.1053/j.gastro.2013.07.050
20. Rodríguez-Cabezas ME, Gálvez J, Camuesco D, Lorente MD, Concha A, Martinez-Augustin O, et al. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr. 2003;22(5):463-71. doi: 10.1016/s0261-5614(03)00045-1
21. Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol. 1999;94(2):427-33. doi: 10.1111/j.1572-0241.1999.872_a.x
22. Ситкин С.И., Ткаченко Е.И., Вахитов Т.Я., Орешко Л.С., Жигалова Т.Н. Особенности метаболома сыворотки крови при язвенном колите и целиакии по данным газовой хроматографии – масс-спектрометрии. Гастроэнтерология Санкт-Петербурга. 2013;3-4:2-10. eLIBRARY ID: 29730010
23. Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107(9):1399-406. doi: 10.1038/ajg.2012.196
24. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn’s disease. Aliment Pharmacol Ther. 2005;21(8):921-31. doi: 10.1111/j.1365-2036.2005.02424.x
25. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462-71. doi: 10.4065/81.11.1462
26. Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol. 2004;2(1):41-8. doi: 10.1016/s1542-3565(03)00290-8
27. Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, et al. Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003;52(4):552-7. doi: 10.1136/gut.52.4.552
28. Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, et al. High smoking cessation rate in Crohn’s disease patients after physician advice--the TABACROHN Study. J Crohns Colitis. 2013;7(3):202-7. doi: 10.1016/j.crohns.2012.04.011
29. Mokbel M, Carbonnel F, Beaugerie L, Gendre JP, Cosnes J. Effet du tabac sur l’évolution à long terme de la rectocolite hémorragique [Effect of smoking on the long-term course of ulcerative colitis]. Gastroenterol Clin Biol. 1998;22(11):858-62. (In French). PMID: 9881267.
30. Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42(4):391-405. doi: 10.1111/apt.13276
31. Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102(8):1692-701. doi: 10.1111/j.1572-0241.2007.01265.x
32. Фарелл Р., Пепперкорн М. Язвенный колит. Международный медицинский журнал. 2003;6(1):73-80.
33. Hu D, Ren J, Wang G, Gu G, Liu S, Wu X, et al. Geographic mapping of Crohn’s disease and its relation to affluence in jiangsu province, an eastern coastal province of china. Gastroenterol Res Pract. 2014;2014:590467. doi: 10.1155/2014/590467
34. Kaplan GG, Hubbard J, Korzenik J, Sands BE, Panaccione R, Ghosh S, et al. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol. 2010;105(11):2412-9. doi: 10.1038/ajg.2010.252
35. Salim SY, Kaplan GG, Madsen KL. Air pollution effects on the gut microbiota: a link between exposure and inflammatory disease. Gut Microbes. 2014;5(2):215-9. doi: 10.4161/gmic.27251
36. Vedani A, Smiesko M, Spreafico M, Peristera O, Dobler M. VirtualToxLab - in silico prediction of the toxic (endocrine-disrupting) potential of drugs, chemicals and natural products. Two years and 2,000 compounds of experience: a progress report. ALTEX. 2009;26(3):167-76. doi: 10.14573/altex.2009.3.167
37. Wagner M, Schlüsener MP, Ternes TA, Oehlmann J. Identification of putative steroid receptor antagonists in bottled water: combining bioassays and high-resolution mass spectrometry. PLoS One. 2013;8(8):e72472. doi: 10.1371/journal.pone.0072472
38. Benchimol EI, Mack DR, Guttmann A, Nguyen GC, To T, Mojaverian N, et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am J Gastroenterol. 2015;110(4):553-63. doi: 10.1038/ajg.2015.52
39. Bernstein CN, Kraut A, Blanchard JF, Rawsthorne P, Yu N, Walld R. The relationship between inflammatory bowel disease and socioeconomic variables. Am J Gastroenterol. 2001;96(7):2117-25. doi: 10.1111/j.1572-0241.2001.03946.x
40. Declercq C, Gower-Rousseau C, Vernier-Massouille G, Salleron J, Baldé M, Poirier G, et al. Mapping of inflammatory bowel disease in northern France: spatial variations and relation to affluence. Inflamm Bowel Dis. 2010;16(5):807-12. doi: 10.1002/ibd.21111
41. Zheng JJ, Zhu XS, Huangfu Z, Gao ZX, Guo ZR, Wang Z. Crohn’s disease in mainland China: a systematic analysis of 50 years of research. Chin J Dig Dis. 2005;6(4):175-81. doi: 10.1111/j.1443-9573.2005.00227.x
42. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60(1):49-54. doi: 10.1136/gut.2010.219683
43. Ballegaard M, Bjergstrøm A, Brøndum S, Hylander E, Jensen L, Ladefoged K. Self-reported food intolerance in chronic inflammatory bowel disease. Scand J Gastroenterol. 1997;32(6):569-71. doi: 10.3109/00365529709025101
44. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15(8):1183-9. doi: 10.1002/ibd.20903
45. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731-6. doi: 10.1073/pnas.0804812105
46. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1720-28. doi: 10.1053/j.gastro.2011.01.054
47. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134(2):577-94. doi: 10.1053/j.gastro.2007.11.059
48. Zaph C, Du Y, Saenz SA, Nair MG, Perrigoue JG, Taylor BC, et al. Commensal-dependent expression of IL-25 regulates the IL-23 -IL-17 axis in the intestine. J Exp Med. 2008;205(10):2191-8. doi: 10.1084/jem.20080720
49. Jess T, Simonsen J, Nielsen NM, Jørgensen KT, Bager P, Ethelberg S, et al. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut. 2011;60(3):318-24. doi: 10.1136/gut.2010.223396
50. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci. 2010;55(2):415-20. doi: 10.1007/s10620-009-0749-9
51. Naser SA, Sagramsingh SR, Naser AS, Thanigachalam S. Mycobacterium avium subspecies paratuberculosis causes Crohn’s disease in some inflammatory bowel disease patients. World J Gastroenterol. 2014;20(23):7403-15. doi: 10.3748/wjg.v20.i23.7403
52. Criscuoli V, Rizzuto MR, Cottone M. Cytomegalovirus and inflammatory bowel disease: is there a link? World J Gastroenterol. 2006;12(30):4813-8. doi: 10.3748/wjg.v12.i30.4813
53. Kim JJ, Simpson N, Klipfel N, Debose R, Barr N, Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010;55(4):1059-65. doi: 10.1007/s10620-010-1126-4
54. Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, Prindiville T, et al. Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol. 2011;50(1):31-6. doi: 10.1016/j.jcv.2010.09.011
55. Schunter MO, Walles T, Fritz P, Meyding-Lamadé U, Thon KP, Fellermann K, et al. Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfections. J Crohns Colitis. 2007;1(1):41-6. doi: 10.1016/j.crohns.2007.06.004
56. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis. 2009;15(1):128-33. doi: 10.1002/ibd.20633
57. Kabeerdoss J, Pugazhendhi S, Subramanian V, Binder HJ, Ramakrishna BS. Exposure to hookworms in patients with Crohn’s disease: a case-control study. Aliment Pharmacol Ther. 2011;34(8):923-30. doi: 10.1111/j.1365-2036.2011.04824.x
58. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, LandryWheeler A, Silver N, et al. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;38(3):255-63. doi: 10.1111/apt.12366
59. Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev. 2014;(1):CD009400. doi: 10.1002/14651858.CD009400.pub2.
60. Abegunde AT, Muhammad BH, Bhatti O, Ali T. Environmental risk factors for inflammatory bowel diseases: Evidence based literature review. World J Gastroenterol. 2016;22(27):6296-317. doi: 10.3748/wjg.v22.i27.6296
61. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(6):751-7. doi: 10.1097/00054725-200411000-00009
62. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(2):196-202. doi: 10.1016/s1542-3565(05)00980-8
63. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(4):352-6. doi: 10.1097/00054725-200407000-00005
64. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002;97(4):910-4. doi: 10.1111/j.1572-0241.2002.05608.x
65. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn’s disease and ulcerative colitis. Am J Gastroenterol. 2011;106(12):2133-42. doi: 10.1038/ajg.2011.304
66. Ungaro R, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a metaanalysis. Am J Gastroenterol. 2014;109(11):1728-38. doi: 10.1038/ajg.2014.246
67. Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn’s disease. Scand J Gastroenterol. 2008;43(8):961-6. doi: 10.1080/00365520801971736
68. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661-73. doi: 10.1038/ajg.2011.72
69. Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, Aerden I, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128(4):856-61. doi: 10.1053/j.gastro.2005.01.010
70. Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103(9):2394-400. doi: 10.1111/j.1572-0241.2008.02064.x
71. Khalili H, Higuchi LM, Ananthakrishnan AN, Richter JM, Feskanich D, Fuchs CS, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013;62(8):1153-9. doi: 10.1136/gutjnl-2012-302362
72. Khalili H, Higuchi LM, Ananthakrishnan AN, Manson JE, Feskanich D, Richter JM, et al. Hormone therapy increases risk of ulcerative colitis but not Crohn’s disease. Gastroenterology. 2012;143(5):1199-1206. doi: 10.1053/j.gastro.2012.07.096
73. Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology. 1998;114(6):1143-50. doi: 10.1016/s0016-5085(98)70419-6
74. Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006;1089:538-47. doi: 10.1196/annals.1386.043
75. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004;229(11):1136-42. doi: 10.1177/153537020422901108
76. Yang L, Weaver V, Smith JP, Bingaman S, Hartman TJ, Cantorna MT. Therapeutic effect of vitamin d supplementation in a pilot study of Crohn’s patients. Clin Transl Gastroenterol. 2013;4(4):e33. doi: 10.1038/ctg.2013.1
77. Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, Zadvornova Y, Binion DG, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35(3):308-16. doi: 10.1177/0148607110381267
78. Jørgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32(3):377-83. doi: 10.1111/j.1365-2036.2010.04355.x
79. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347(12):911-20. doi: 10.1056/NEJMra020100
80. Baron S, Turck D, Leplat C, Merle V, Gower-Rousseau C, Marti R, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut. 2005;54(3):357-63. doi: 10.1136/gut.2004.054353
81. Дорофеев А.Э. Диагностика и лечение заболеваний пищеварительного тракта. Донецк: Норд¬Пресс; 2009. ISBN: 978-966-380-283-1
82. Russel MG, Dorant E, Brummer RJ, van de Kruijs MA, Muris JW, Bergers JM, et al. Appendectomy and the risk of developing ulcerative colitis or Crohn’s disease: results of a large casecontrol study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology. 1997;113(2):377-82. doi: 10.1053/gast.1997.v113.pm9247453
83. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn’s disease and their relatives. A possible etiologic factor. Ann Intern Med. 1986;105(6):883-5. doi: 10.7326/0003-4819-105-6-883.
84. Дурлештер В.М., Корочанская Н.В., Вершинина Г.А. Современные представления об этиологии язвенного колита. Научный вестник Здравоохранения Кубани. 2014;32(2):73-83. eLIBRARY ID: 21969185
85. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008;57(9):1185-91. doi: 10.1136/gut.2007.122143
Supplementary files
Review
For citations:
Tkachev A.V., Mkrtchyan L.S., Mazovka K.E., Bohanova E.G. In the labyrinths of pathogenesis: the environment and metamorphosis of IBD. South Russian Journal of Therapeutic Practice. 2021;2(3):30-39. (In Russ.) https://doi.org/10.21886/2712-8156-2021-2-3-30-39
Views:
731
Email this article 